gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · RCUSHealthcarePharmaceuticals

Arcus Biosciences, Inc. (RCUS)

$19.31+2.12%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$19.31▼ 2.62% in range
Nov 4, 2025Low $17.76 · High $31.57Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Arcus Biosciences closed at $19.31 on Nov 4, up 2.12%, 38.8% below its 52-week closing high. Volume of 2.1M shares was 0.78× its 20-day average (below normal).

Split-adjusted performance: -20.5% over one month, -25.7% over six months, -5.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $41M, down 74.4% from a year earlier, with a net margin of -222.0%.

Short interest was 12.4M shares at the Oct 15 settlement, down 5.7% from the prior report (13.6% of float, 9.7 days to cover).

Market cap$2.46B127.3M shares
Revenue · quarter$41.0M−74.4% YoY
Diluted EPS$-0.72—
P/E · TTM—P/S 21.0×
Net margin-222.0%Gross 100.0%
Dividend yieldNone
52-week range17.76 – 31.57−38.8% from high
Volume2.1M0.78× 20-day avg
Volatility · 60d64.2%Annualised
Short % of float13.6%9.7 days to cover
Net cash$601.0MCash $702.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +5.0%1M −20.5%3M −31.8%6M −25.7%YTD −19.0%1Y −5.1%3Y +29.2%5Y −41.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum50
Revenue growth17
Net margin36
Value (low P/E)—
Size84

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short12.4M−5.7% vs prior
Days to cover9.7Settled Oct 15
% of float13.6%
Short vol. 10d46.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
RCUSArcus Biosciences$19.31+2.12%−25.7%−74.4%−222.0%—$2.46B
NAMSNewAmsterdam Pharma Company N.V$20.93+5.18%−32.5%−80.7%−1732.9%—$2.50BCompare
PBHPrestige Consumer Healthcare$53.28+7.55%−1.9%+6.5%11.0%14.7$2.52BCompare
MBXMBX Biosciences$52.48−4.58%+63.4%———$2.53BCompare
PVLAPalvella Therapeutics$162.28+6.11%+24.7%———$2.34BCompare
XNCRXencor$35.03+14.33%+169.3%+17.5%−42.4%—$2.60BCompare
VERAVera Therapeutics$31.97+4.10%−12.6%———$2.30BCompare
IMNMImmunome$19.52−3.89%−16.1%−100.0%——$2.30BCompare
BHVNBiohaven$15.24−2.37%+51.8%———$2.30BCompare

News about Arcus Biosciences

All news →
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% RunThe Motley Fool · Jul 13, 2026Neutral

Quick answers

What does Arcus Biosciences do?
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others.
What is RCUS's market cap?
$2.46B, based on the Nov 4 close of $19.31.
Does Arcus Biosciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of RCUS is sold short?
12.4M shares, 13.6% of float, as of Oct 15, 2026.
What sector is RCUS in?
Healthcare, in the Pharmaceuticals industry.

About Arcus Biosciences

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

HQ: Hayward, CA601 employeesListed Mar 15, 2018arcusbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology